Factor VLeiden

Activated protein C resistance testing for factor V Leiden

(2014) Stephan Kadauke et al.   AMERICAN JOURNAL OF HEMATOLOGY

The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays

(2014) Y. A. Kim et al.   International Journal of Laboratory Hematology

Activated Protein C Resistance Assay and Factor V Leiden

(2014) Florian Prüller et al.   NEW ENGLAND JOURNAL OF MEDICINE

A novel factor V mutation causes a normal activated protein C ratio despite the presence of a heterozygousF5R506Q (factor V Leiden) mutation

(2013) Florian Prüller et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Effect of Dabigatran on Select Specialty Coagulation Assays

(2012) Dorothy M. Adcock et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Acquired Activated Protein C Resistance Caused by Lupus Anticoagulants

(2011) Adam J. Saenz et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

All that glitters is gold?

(2010) Elizabeth M. Van Cott   AMERICAN JOURNAL OF HEMATOLOGY

Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays

(2010) A. HILLARP et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The Effect of Argatroban on Activated Protein C Resistance

(2009) Salima Shaikh et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Laboratory Evaluation of Hypercoagulability

(2009) Bernard Khor et al.   CLINICS IN LABORATORY MEDICINE

Screening With the Activated Protein C Resistance Assay Yields Significant Savings in a Patient Population With Low Prevalence of Factor V Leiden

(2008) Laura J. Taylor et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Factor V Leiden: Is it the chief contributor to activated protein C resistance in Asian-Indian patients with deep vein thrombosis?

(2008) Arijit Biswas et al.   CLINICA CHIMICA ACTA

Increased acquired activated protein C resistance in unselected patients with hematological malignancies

(2008) H. F. S. NEGAARD et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS